Fosun Pharma’s Subsidiary Gains Approval for New Drug Application

Tip Ranks
2025.11.18 10:09
portai
I'm PortAI, I can summarize articles.

Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder from the National Medical Products Administration. This drug targets chronic constipation and represents a significant R&D investment of RMB6.21 million. The approval could strengthen Fosun Pharma's market position in China. The latest analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a target price of HK$35.30.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received acceptance for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder by the National Medical Products Administration. This drug is intended for treating chronic constipation and represents a significant investment in research and development by the company, totaling approximately RMB6.21 million. The acceptance of this application could enhance Fosun Pharma’s market positioning in the pharmaceutical industry, particularly in China, where the demand for such treatments is growing.

The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market focus on both domestic and international healthcare sectors.

Average Trading Volume: 8,192,263

Technical Sentiment Signal: Buy

Current Market Cap: HK$79.56B

For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.